+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Erythropoietin Stimulating Agents Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4520175
  • Report
  • 113 pages
  • Mordor Intelligence
1 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • Biocon Limited
  • BioSidus
  • Celltrion, Inc
  • F. Hoffmann-La Roche Ltc
  • Intas Pharmaceuticals Ltd
  • MORE
Market Overview

Over the past decade, anemia is one of the serious diseases related to nutrition, accompanied by increased morbidity and mortality. In the major developing countries, neonatal and maternal mortality accounted for 3.0 million deaths, in 2013, and are considered as the important contributors to global mortality.

According to the WHO, in 2013, it was estimated that pregnant women (38%), non-pregnant women (29%), children (43%), and women of reproductive age (29%) suffer from anemia, corresponding to 496 million non-pregnant women, 273 million children, and 32 million pregnant women, globally. Further, the proportion of children and women is maximum in the African region where around 57% of pregnant women (17 million), 48% of non-pregnant women (70 million), and 68% of preschool children (84 million) are anemic.

In developed countries, the deficiency of iron is one of the major causes of anemia and insufficient red blood cells production. Other causes of anemia include parasite infections, such as Ascaris, schistosomiasis, and hookworms that can lower blood hemoglobin (Hb) concentrations and cause heavy blood loss during menstruation. Chronic infections, including tuberculosis, malaria, HIV, and cancer can also lower blood Hb concentrations. As the number of people affected by anemia increases, there is an increase in demand for erythropoietin stimulating agents.

Hence, with the increasing anemia burden, propels the demand for existence and growth of this market.

Scope of the Report

Erythropoietin stimulating agents are similar to erythropoietin, as it stimulates the growth of red blood cells. ESAs have been approved for the treatment of anemia, due to chronic kidney failure, chemotherapy, HIV, and also for reduced red blood cells, during critical surgical procedures.

Key Market Trends

Cancer Dominates the Studied Market in the Application Segment

Anemia is observed in the majority of patients undergoing cancer treatment. The severity of the disease in the patients depends on the type of chemotherapy used, type and stage of neoplasia, and patient characteristics. Anemia results in fatigue, weakness, and depression; these factors severely reduce the quality of life of cancer patients.

In addition, anemia impairs the efficacy of cancer therapies. Clinical trials have shown that treating anemia associated with cancer with erythropoietin has improved the quality of life. Erythropoietin acts against two main causes of anemia in cancer patients undergoing chemotherapy, i.e. against myelosuppression and endogenous erythropoietin deficiency. Patients with cancer-related anemia are commonly prescribed erythropoietin in the form of epoetin alfa and epoetin beta. Top prescribed products include Procrit, Epogen, and NeoRecormon. With more than 75% of the patients suffering from anemia, due to cancer chemotherapy, the demand for erythropoietin stimulating agents increases. Hence, with the increase in cancer patients undergoing chemotherapy, the global market is expected to grow during the forecast period.

North America is Believed to Hold the Largest Market Share in the Forecast Period

Erythropoietin stimulating agents have been effectively used in various chronic diseases, like chronic kidney disease (CKD), cancer, neural, and HIV patients. For instance, the Center for Disease Control and Prevention (CDC) estimates that more than 10% of adults in the United States have CKD. The chances of having CKD increases with age and is common among adults older than 70 years. Moreover, adults with diabetes or higher blood pressure are prone to CKD, as well.

According to the CDC, in 2016, about 29 million people lived with diabetes, and about 86 million were in the pre-diabetic stage. According to the United States Department of Health and Human Services, the older population (65 years or more) numbered 46.2 million, in 2014, which represented about 14.5% of the country population. Further, the percentage share of the older population is expected to reach 21.7%, by 2040. Also, this number is expected to be around 98 million, by 2060. Increasing people with a higher risk for CKD is expected to accelerate market growth.

Competitive Landscape

The market studied is moderately consolidated and it is inclusive of the global as well as local companies. Some of the key players in the market are Amgen, Thermo Fisher Scientific, Johnson and Johnson, F.Hoffmann La Roche and Pfizer.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • Biocon Limited
  • BioSidus
  • Celltrion, Inc
  • F. Hoffmann-La Roche Ltc
  • Intas Pharmaceuticals Ltd
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Disease Burden of Anemia
4.2.2 Growing Applications in HIV and End-stage Renal Disorder
4.2.3 Risks of Thrombosis during Surgery and Pure Red Cell Aplasia
4.3 Market Restraints
4.3.1 Stringent Regulatory Guidelines
4.3.2 Adverse Side Effects
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Epoetin - Alfa
5.1.2 Epoetin - Beta
5.1.3 Darbepoetin - Alpha
5.1.4 Others
5.2 By Application
5.2.1 Cancer
5.2.2 Renal Disorders
5.2.3 Anti-retroviral Treatment
5.2.4 Neural diseases
5.2.5 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amgen Inc.
6.1.2 BioSidus
6.1.3 Biocon Limited
6.1.4 Celltrion, Inc
6.1.5 F. Hoffmann-La Roche Ltc
6.1.6 Intas Pharmaceuticals Ltd
6.1.7 Johnson and Johnson
6.1.8 Pfizer, Inc
6.1.9 Teva Pharmaceutical Industries Ltd
6.1.10 Thermo Fisher Scientific

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Amgen Inc.
  • BioSidus
  • Biocon Limited
  • Celltrion, Inc
  • F. Hoffmann-La Roche Ltc
  • Intas Pharmaceuticals Ltd
  • Johnson and Johnson
  • Pfizer, Inc
  • Teva Pharmaceutical Industries Ltd
  • Thermo Fisher Scientific
Note: Product cover images may vary from those shown
Adroll
adroll